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Summary 
IgE synthesis  requires  interleukin 4 (IL-4) and a T-B cell interaction that involves the B cell 
antigen CD40 and its ligand expressed on activated T cells. IL-4 induces e germline transcription 
whereas ligation of CD40 results  in deletional S# ~  Se switch recombination, expression  of 
mature E transcripts, and IgE synthesis and secretion. We demonstrate that disodium cromoglycate 
(DSCG), a drug commonly used for the prophylactic treatment of allergic disease, inhibits T 
cell-driven IgE synthesis by human B cells at concentrations readily achievable in the course 
of inhaled therapy for asthma. Inhibition of IgE synthesis by DSCG was not the result of drug 
toxicity because DSCG did not affect the viability of T and B cells or their proliferation to mitogens. 
DSCG did not interfere with CD40 ligand expression by T cells but clearly targeted the B cells 
because it inhibited IgE synthesis induced by anti-CD40 and IL-4 in populations of highly purified 
B cells. DSCG had no effect on the induction of E germline transcripts by IL-4 but strongly 
inhibited CD40 mediated S# --* Se deletional switch recombination in IL-4-treated B cells as 
assayed by nested primer PCR. The effect of DSCG was not specific for CD40-mediated induction 
of IgE isotype switching because DSCG inhibited IgE synthesis as well as S# ~  Se deletional 
switch recombination induced by hydrocortisone and IL-4 in B cells. Moreover,  the effect of 
DSCG was not specific for IgE isotype switching because DSCG inhibited the synthesis of IgG4 
by B cells sorted for lack of surface expression of IgG4 and stimulated with anti-CD40 and IL- 
4. DSCG caused only minimal inhibition (<15 %) of spontaneous IgE synthesis by lymphocytes 
from patients with the hyper-IgE syndrome and did not affect pokeweed mitogen-induced IgG 
and IgA synthesis by lymphocytes suggesting that it has little effect on B cells that have already 
undergone isotype switching. These results  indicate that DSCG inhibits switching to IgE in 
B cells and suggest a novel potential mechanism for the prevention of allergic disease by DSCG. 
D 
isodium cromoglycate (DSCG) 1, the salt of a bis-chro- 
mone carboxylic  acid,  has an established  role in the 
prophylactic treatment of bronchial asthma, allergic rhinitis, 
and conjunctivitis (1, 2). Despite intensive research, the pre- 
cise mechanisms by which DSCG exerts its clinical activity 
are still poorly understood. The primary mode of action of 
cromolyn sodium was thought to be stabilization  of mast 
cells and subsequent prevention of mediator release after an- 
tigen challenge (3-6). More recently, DSCG was shown to 
inhibit the in vitro  activation of human neutrophils, eo- 
1Abbreviations used in  this paper: AET, 2-aminoethyl  isothiouronum 
bromide; DSCG, disodium cromoglycate; GaMIg, goat anti-mouse IgG; 
HC, hydrocortisone;  PKC, protein kinase  C; FFK, protein tyrosine kinase; 
r, recombinant. 
R. K. S. Loh and H. H. Jabara contributed  equally to this work. 
sinophils, and monocytes (7). Little is known about the effect 
of DSCG on IgE production except for a single report in 
which DSCG was found to inhibit spontaneous as well as 
IL-4-induced IgE production (8). 
Induction of IgE synthesis in human B cells requires two 
signals. The first signal is delivered by the cytokine IL-4 and 
results  in e germline transcription but not in IgE isotype 
switching (9,  10). A  second signal is required for isotype 
switching and IgE synthesis and secretion. This second signal 
is normally delivered by T cells (11, 12). We have previously 
shown that the T cell signal can be replaced by mAb to CD40 
(13), Epstein-Barr virus (14), and hydrocortisone (HC) (15). 
Addition of any of these agents to IL-4-treated B cells results 
in deletional S# ~  Se switch recombination, expression of 
mature e transcripts, and IgE synthesis and secretion (16). 
Interaction between CD40 and its ligand appears to play 
an important role in T cell-dependent isotype switching to 
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T cells express a ligand for CD40 (18) and that a soluble form 
of the CD40 ligand inhibits T cell-driven isotype switching 
to IgE in IL-4-treated B cells (19). Furthermore, Epstein- 
Barr virus-transformed B cells transfected with the CD40 
ligand replace T cells in synergizing with IL-4 to induce IgE 
synthesis in B cells (20). 
We herein demonstrate that DSCG inhibits IL-4-driven 
T cell-dependent IgE synthesis by PBMC from the majority 
('~65%) of normal human subjects as well as IgE synthesis 
by B cells stimulated with anti-CD40  +  IL-4 or with HC 
+  IL-4. DSCG did not interfere with CD40 ligand expres- 
sion by T  cells after stimulation by PMA and ionomycin. 
It also had no effect on the induction of e germline tran- 
scripts by IL-4 but strongly inhibited CD40-mediated dele- 
tional switch recombination in IL-4-treated B cells. Further- 
more, DSCG inhibited isotype switching in B cells to IgG4. 
These results strongly suggest that DSCG acts directly on 
B cells to inhibit immunoglobulin class switching in B cells. 
Materials and Methods 
Cell Preparation, Cell Culture, and IgE Assay.  Highly purified B 
cells from nonatopic subjects were prepared as previously  described 
(11). In summary, PBMC from healthy subjects were isolated by 
density gradient centrifugation,  rosetted  twice with 2-amino- 
ethylisothiouronium bromide (AET)-treated SRBC, and treated 
twice with anti-CD3 mAB (OKT3; Ortho Diagnostics, Raritan, 
NJ) plus rabbit complement (Pel-Freeze  Biologicals, Rogers, AR). 
Monocytes were removed  by adherence to plastic petri dishes. The 
B cell-rich populations thus obtained contained <1% CD3 + cells, 
and did not proliferate  in response to PHA (10/~g/ml)  but strongly 
proliferated  in response to PMA (25 ng/ml) + ionomycin  (0.5/~M). 
PBMC were also isolated from two patients with hyper-IgE syn- 
drome whose serum IgE was ,-3,000 U/ml and ,~10,000 U/m1, 
respectively. 
PBMC and B cells  were suspended  in RPMI 1640 supplemented 
with 10% fetal calf serum (Hyclone Sterile Systems, Inc., Logan, 
UT), 2 mM L-glutamine,  100 U/ml penicillin, and 50 #g/m1 strep- 
tomycin (complete medium) in the presence or absence of Ib4 (50 
U/ml) and anti-CD40 mAb (5/xg/ml) or PWM (1/~g/ml). Con- 
trol cultures for the evaluation  of preformed immunoglobulin were 
set up in the presence of cycloheximide  (100 mg/ml; Sigma Chem- 
ical Co., St. Louis, MO). At day 10 of cuhure, supernatants were 
assessed for their IgE level by a radioimmunoassay (ILIA) with a 
sensitivity limit of 150 pg/ml (21). IgG4 levels were determined 
by a commercially available  ELISA assay (The Binding Site, Ltd., 
Birmingham, UK) with a lower limit of sensitivity of 2.1 ng/ml. 
IgG, IgA, and IgM levels were determined by ELISA, as previously 
described (21). Net IgE synthesis  was calculated  by subtracting the 
values of preformed IgE. 
Reagents.  DSCG, obtained as a gift from Fisons Pharmaceu- 
ticals (Loughborough,  UK),  is  a  disodium  salt of  1,3-bis(-2 
carboxychromon-5-yloxy)  2-hydroxypropane.  DSCG was dissolved 
in water at 10-2 M and filtered through a filter (Millipore Corp., 
Bedford, MA). DSCG was further diluted in complete medium. 
Human recombinant (r)IL-4 (specific activity 2  x  107 U/rag) was 
obtained from Amgen Biologicals  (Thousand Oaks, CA) and the 
anti-CD40 mAb 626.1 has previously  been described (22). PHA, 
PMA, Con A, AET, and ionomycin were purchased from Sigma 
Chemical Co. [3H]Thymidine  and Econofluor  were from New En- 
gland (Boston, MA). sCD40 and sCD44 were products of fusion 
of cDNA segments encoding the extracellular domain of CD40 
(23) and CD44 (24) to genomic DNA segments encoding human 
IgG1 (18) and were purified on a protein A column. 
Assays for B Cell Proliferation.  For proliferation assays, B cells 
were cultured in 96-well flat-bottomed  plates (Nunc, Roskilde,  Den- 
mark) at 10  s cells/well in 200/~1 complete medium for 72 h in 
the presence or absence of the indicated stimuli. The cultures were 
then pulsed with [3H]thymidine at 1/~Ci/well  for an additional 
16  h,  harvested, and  [3H]thymidine incorporated into  cellular 
DNA was counted. 
Cell Su~ce Expression  of  the CD40 Ligand.  T cells, isolated  from 
PBMC by rosetting once with AET-treated SRBC, were left un- 
treated or were stimulated with 20 ng/ml PMA,  and 0.5 /~M 
ionomycin. The cells were then suspended in staining buffer and 
incubated successively  for 30 min on ice with 20/~g/ml sCD40 
or  sCD44  as  a  control,  10  #g/ml  biotinylated  Protein  G 
(Calbiochem-Novabiochem  Corp., La Jolla, CA), and phycoerythrin- 
labeled Streptavidin (R & D Systems, Inc., Minneapolis, MN) as 
previously described (25). Fluorescence was  examined using  a 
FACScan  |  (Becton Dickinson & Co., Mountain View, CA). 
Cell Sorting.  To obtain highly purified  B cells, B cell-rich popu- 
lations of  cells were labeled  with FITC-conjugated  anti-CD19 mAb, 
and sorted on a FACStar  +0 flow cytometry (Becton Dickinson & 
Co.). Setting of the markers and analysis of the sorted cells were 
performed as previously described (13). 
Enriched populations of B cells were depleted of surface IgG4- 
bearing B cells by magnetic cell sorting using mouse anti-human 
IgG4 mAb (The Binding Site, Ltd.) and magnetic beads coated 
with goat anti-mouse IgG (GaMIg). Depletion of surface IgG4  + 
|  cells was monitored by FACS  analysis  using mouse anti-human 
IgG4 mAb and fluorescein-conjugated  GaMIg. 
Northern Blot Analysis.  Total  cellular RNA was prepared by cell 
lysis with guanidium isothiocynate followed by centrifugation of 
the lysate through a cesium chloride step gradient. Northern blot 
analysis was carried out with 10 #g of total cellular RNA using 
32p-labeled gel purified DNA probes. A 0.88-kb Hint fragment 
that spans the first two exons of C~ detects both germline and 
mature Ce transcripts. The human cDNA ~-actin probe was kindly 
provided by Dr. C. Terhorst (Beth Israel Hospital, Boston, MA). 
Prehybridization, hybridization,  washing, and autoradiography  con- 
ditions were as previously described (13). Densitometric analysis 
was performed with a densitometer (Ultrascan XL; LKB Instru- 
ments, Bromma, Sweden). 
PCR Primers~Amplification, Cloning, and Sequencing of S/~/Se 
"Switch Fragments."  High molecular weight DNA was prepared 
from 5-10  x  1@ cultured B cells using the A.S.A.P. genomic 
DNA  Isolation Kit  (Boehringer Mannheim  Biologicals, Indi- 
anapolis, IN). Nested primer PCR analysis  for S#/Se switch frag- 
ments was performed  on high molecular  weight DNA isolated  from 
cultured B cells using the following four primers as previously  de- 
scribed (26): S6:5'-CTGCAGACTCAGAAGC~AGGC~ATC.-CT- 
CCG-Y; $4:  3  ~  -  ACTGATCCAAGACAGGAGTG'[GC~GGATGT  - 
5';  $7: 5'-GAGGGTGGTAATGATTGGTAATGCTTTGGA-Y; 
S9:3'-GAACCCTGAGGTCCGGTCCCCGCTTCCCGG-5'. 
The first round of PCR was performed using primers $6/$4. 
The second round of PCR was performed on a 5-/~1 aliquot of 
the  first round  PCR  mixture  with  primers $7/$9.  PCR 
amplification  and purification of the amplified  fragments were car- 
tied out as previously described (26). 
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Effect of DSCG on IgE production by PBMC in the pres- 
ence of Ib4 (50 U/ml). PBMC at a concentration of 1.5  x  106 calls/m1 
were cultured for 10 d with different concentrations of DSCG. Superna- 
tants were harvested after 10 d and IgE levels were measured by R.IA. 
Values represent mean _+ SE net synthesis IgE (pg/ml) of five experiments. 
Results 
DSCG Inhibits IL-4-induced IgE Synthesis by PBMC.  We 
first examined the effect of 10 -6 M DSCG on IgE synthesis 
induced by IL-4 in PBMC. We chose this concentration of 
DSCG because it is in the range of the peak DSCG level mea- 
sured in the serum of patients after inhalation of the drug 
(7).  1 #M DSCG caused virtually complete inhibition (>85% 
inhibition)  of IgE synthesis by PBMC in 11 of 17 subjects 
studied. In the remaining six subjects inhibition was <50%. 
Because of this bimodal distribution we focused the remainder 
of our studies on subjects whose PBMC were susceptible to 
inhibition  by DSCG. Fig.  1 shows that DSCG inhibits IgE 
synthesis by PBMC stimulated with IL-4 in a dose-dependent 
manner with 50% inhibition  of IgE occurring at a concen- 
tration of DSCG of 10 -s M. 
Induction of IgE synthesis by IL-4 in PBMC is T cell-de- 
pendent and involves interaction between the B cell antigen 
CD40 and the CD40 ligand expressed on activated T cells. 
DSCG  had no effect  on either T  cell viability as assessed by 
trypan blue dye exclusion or T cell proliferation to anti-CD3 
mAb, PHA, the superantigen TSST-1,  and tetanus toxoid 
MEDIUM 
1  2  3 
DSCG 
:: ii 
1  2  3 
LOG  FLUORESCENCE 
Figure  2.  Cell surface expression of the CD40 ligand. T cells were left 
untreated (dotted  line) or stimulated with PMA  +  ionomycin (solid line). 
CD40 ligand expression with or without DSCG was assessed at 6 h. There 
was no detectable binding of sCD44 with or without stimulation  (data 
not shown). 
(data not shown). More importantly, DSCG did not inter- 
fere with CD40 ligand expression by T cells after stimula- 
tion by PMA and ionomycin (Fig. 2). These results suggested 
that the inhibitory effect of DSCG on IgE synthesis may be 
exerted at the level of the B cells. 
DSCG  Inhibits IL-4/CD40-induced  IgE  Synthesis in  B 
Cells.  To determine whether DSCG can exert its effect in- 
dependent ofT cells, we assessed the effect of DSCG on IgE 
synthesis by a purified B cell population  depleted of T cells 
(<1% CD3 * T cells) and stimulated with anti-CD40 mAb 
and IL-4. Fig. 3 A  shows that anti-CD40 mAb 626.1 plus 
IL-4-induced  vigorous  IgE synthesis in these B cells. Addi- 
tion of DSCG resulted in a dose-dependent inhibition of IgE 
synthesis by B cells. There was ,,o50% inhibition oflgE syn- 
thesis at  a  concentration  of DSCG  of  10 -s  M  and  >85% 
inhibition  at  a  concentration  of  10 -4  DSCG. 
To unequivocally establish a direct effect of DSCG on B 
cells, we prepared highly purified B cells by cell sorting for 
CD19 positive cells. Upon reanalysis, these populations con- 
sisted of >98%  CD19 + cells. Fig. 3 B  shows  that DSCG 
inhibited IgE synthesis triggered by anti-CD40  +  IL-4 in 
these B cells. These results indicate that B cells are targets 
for inhibition  by DSCG. 
There was no evidence of DSCG toxicity to purified B 
cells. Fig. 4 shows that these B cells failed to proliferate to PHA 
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Figure  3.  (A)  Effect of  DSCG  on  IgE 
production by T cell-depleted B cell-enriched 
populations of calls in the presence of Ib4 (50 
U/ml) and anti-CD40 inAb (5 #g/ml). Cells 
were  cultured  at  a  concentration  of  106 
cells/ml for 10 d with different concentrations 
of DSCG.  Supernatants were harvested after 
10 d and IgE levels were measured by RIA. 
Results represent mean _+ SE net synthesis IgE 
(pg/ml) of five experiments. (B) Effect of DSCG 
on IgE production by highly purified B cells 
isolated by sorting for CD19 expression. B cells 
were cultured as described in A. Similar results 
were observed in a second experiment. 
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Figure 4.  B cells were induced to proliferate by either PMA (20 ng/ml) 
and ionomycin (0.5/~M) or Ib4 (50 U/ml) and anti-CD40 mAb (5/~g/ml). 
The B cells were cultured for 72 h at 2  x  10  s cells/well in 200/~1 in the 
presence and absence of DSCG. During the last 16 h of culture [3H]TdR 
was added to the culture. Results are mean ~m _+ SE of three experiments. 
IL-4. Addition of DSCG at concentrations up to 10 -4 M did 
not inhibit  B cell proliferation.  Furthermore, addition of 
DSCG to B cells stimulated with anti-CD40  +  IL-4 to mimic 
the conditions used for IgE synthesis did not decrease cell 
viability at the end of the 10-d culture period as assessed  by 
trypan blue dye exclusion (data not shown). 
DSCG Does Not Inhibit 11..-4 Induction of e Germline  Tran- 
scripts in B Cells.  The effect of  DSCG on IgE synthesis could 
be exerted at the level of induction of e germline transcrip- 
tion by IL-4 or at the level of CD40-mediated switch recom- 
bination or at both levels. Fig. 5 A  shows that DSCG did 
not affect the accumulation of e germline transcripts  in B 
cells treated with IL-4. In three experiments, the mean ratio 
of ~ germline transcript  to actin of B cells stimulated with 
IL-4 in the presence of DSCG was 1.08  +  0.08-fold  that 
of B cells stimulated with IL-4 in the absence of DSCG as 
determined by densitometry. DSCG by itself did not induce 
detectable e germline transcripts  (data not shown). 
We have previously shown that engagement of CD40 by 
anti-CD40 mAb upregulates e germline transcription induced 
by IL-4 (26). Fig. 5 B shows that DSCG did not affect the 
upregulation of IL-4 e germline transcription by anti-CD40. 
In three experiments, the mean ratio ore germline transcript 
to actin of B cells stimulated  with IL-4 in the presence of 
DSCG was 1.04 _+ 0.09-fold that of B ceUs stimulated with 
IL-4 and CD40 in the absence of DSCG as determined by 
densitometry. These results strongly suggest that inhibition 
of IgE synthesis by DSCG is not due to interference with 
rIL-4 induction of e germline transcripts. 
DSCG Inhibits CD40-mediated Induction of  Switch Recombi- 
nation in B  Cells.  We have previously shown that addition 
of anti-CD40 mAb to B cells treated with IL-4 results in 
deletional switch recombination as demonstrated by nested 
Figure 5.  (A) Effect of DSCG on the induction of germline Ce tran- 
scripts in B ceUs stimulated with I1--4. Total RNA (10/~g) was prepared 
from normal peripheral blood B cells incubated with medium or Ib4 (50 
U/ml) or IL-4 (50 U/ml) and DSCG (10 -6 M) for 5 d then dectropho- 
resed on a 1% formaldehyde-agarose gd, transferred to a nitrocellulose 
membrane, and hybridized to a 32p-labded  0.88-kb Hinfl fragment. Den- 
sitometric analysis  was performed on germline Ce transcripts mRNA bands 
vs. actin transcript mRNA. The autoradiograph  was exposed  for 5 d. Similar 
resuhs were obtained in two additional experiments. (B) Effect of DSCG 
on induction of germline Ce transcripts in B cells stimulated with IL-4 
and anti-CD40. Total RNA (10/~g) was prepared from normal peripheral 
B cens incubated with medium or II:4 (50 U/ml) plus anti-CD40 mAb 
(5/~g/ml) or 1I.-4 (50 u/m1) plus anti-CD40 mAb (5/~g/ml) and DSCG 
(10 -6 M) for 5 d then proceeded as described for Fig. 6 except that the 
autoradiograph was exposed for only 3 d. Similar results were obtained 
in two additional experiments. 
primer PCR amplification of recombined S/~/Se regions. To 
determine whether DSCG interferes with switch recombi- 
nation, we performed nested primer PCR amplification of 
recombined S/~/Se regions  on DNA isolated from B cells 
stimulated with IL-4 and anti-CD40 in the presence or ab- 
sence of DSCG.  Fig. 6 shows that 10 -6 M DSCG strongly 
inhibited the generation of  S/~/Se switch fragments. The pres- 
ence of a single band in each of the two lanes loaded with 
the highest amount of DNA from B cells cultured with anti- 
CD40 +  IL-4 and DSCG compared with the multiple bands 
666  Disodium Cromoglycate  Inhibits IgE Synthesis by Human B Cells Figure  6.  Effect  of 10 -6 M DSCG on the generation of S# ~  Se 
switch fragments  in B cells stimulated  with anti-CD40 + I1.-4. Serially 
diluted aliquots of total  cellular  DNA from  B cells stimulated  with IL-4, 
IL-4 plus anti-CD40 mAb, or IL-4  plus anti-CD40  mAb and DSCG (10 -6 
M) were amplified  by nested  PCK. The serially  diluted template  DNA 
sample amounts  used in the first round of PCR are noted above the gel. 
The second  round  or nested  round  of  PCR used 10% of the original  PCR 
reaction mixture as DNA template. Final  PCR products were subjected 
to agarose  gel electrophoresis.  PCR amplifiable  DNA was present in all 
three samples, as evident  by the control  (C) band  for which  primers  specific 
for the human  IL-1/$  promoter (-1323/+ 72) yield  a 1.4-kb fragment  by 
PCK. MW, molecular  weight markers. 
seen in lanes loaded with equivalent amounts of DNA from 
B cells cultured with anti-CD40  +  IL-4 is not unexpected 
given the fact that in the experiment shown the inhibition 
of IgE synthesis by DSCG was not complete (2,274  pg/ml 
in the presence  of DSCG vs.  16,348 pg/ml in control cul- 
tures; inhibition 86%).  These results strongly suggest that 
DSCG inhibits CD40-mediated deletional switch recombi- 
nation. 
DSCG Inhibits HC-mediated Induction of lgE Synthesis and 
Switch Recombination in IL-4-treated B Cells.  We have previ- 
ously shown that HC  +  IL-4 induces IgE synthesis in B 
cells (15). This is accompanied by ddetional switch recombi- 
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Figure  7.  Effect  of DSCG on IgE production induced in B cells by 
hydrocortisone (10 -6 M) and IL4 (50 U/ml). Values represent mean _+ 
SE net synthesis  IgE (pg/ml) of three experiments. 
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Figure  8.  Effect  of"  DSCG on the generation  of S/t -,. Se switch  frag- 
ments in B cells stimulated  with HC+II.r4. Serially  diluted aliquots of 
total cellular  DNA from B cells stimulated  with Ib4, IL-4  plus HC, or 
II:4 plus HC and DSCG (10 -6 M) were amplified  by nested PCR as de- 
scribed  for Fig. 6. PCK amplifiable  DNA was present  in all three  samples, 
as evident  by the control  (C) band  for which  primers specific  for the human 
ILl B promoter (-1323/+72) yield a 1.4-kb fragment  by PCK. MW, 
molecular weight markers. 
IgE isotype switching is restricted to CD40, we examined 
the effect of DSCG on IgE isotype switching induced by 
HC +  IL-4. Fig. 7 shows that DSCG inhibited IgE synthesis 
induced by HC  +  IL-4 in B cells. The dose-response  curve 
of this inhibition was similar to that seen with anti-CD40 
+  IL-4. Fig. 8 shows that DSCG completely inhibited the 
generation of S#/Se switch fragments in B cells treated with 
HC +  IL-4. These results suggest that the inhibitory effect 
of DSCG on IgE isotype switching is not specific to CD40 
but targets switch recombination. 
DSCG Inhibits Isotype Switching to IgG4 in B Cells Stimu- 
lated with Anti-CD40  and  11..-4.  Immunoglobulin  class 
switching is thought to involve events that are common to 
all isotypes as well as events  that are isotype specific (28). 
It was therefore important to determine whether the inhibi- 
tory effect of DSCG on isotype switching was restricted to 
IgE or also extended to other isotypes. Because IL-4 also directs 
switching to  IgG4,  we examined the effect  of DSCG  on 
IgG4  synthesis in B  cells  stimulated with  IL-4  and  anti- 
CD40. To ensure that we were measuring isotype switching, 
and not merely amplification of immunoglobulin secretion 
by B cells that had already undergone isotype switching, we 
used B cells that were magnetically sorted for lack of IgG4 
surface expression.  Fig.  9 depicts the FACS  |  analysis of B 
cells before and after sorting. There was no detectable sur- 
face expression  of IgG4 in the negatively sorted B cells. To 
ensure that the effect of DSCG was not exerted at the level 
of IL-4 induction of ~/4 germline transcription,  we prein- 
cubated the B cells for 3 d with IL-4 to allow for optimal 
expression  of germline transcripts, then stimulated the cul- 
tures with anti-CD40 with or without DSCG. Fig. 10 shows 
that unstimulated slgG4- B cells secreted no detectable IgG4 
or IgE into their supernatants. Anti-CD40  +  IL-4 induced 
the secretion  of IgG4 and IgE whereas none of these two 
agents  by  itself caused  IgG4  or  IgE  synthesis  (data  not 
shown). Because of the low number orb cells recovered post A  B 
,d~  ~dt 
Relative Fluorescence Intensity 
Figure 9.  FACS  |  analysis of 
purified purified B cells subjected 
to magnetic cell sorting to deplete 
IgG4-bearing  ceils. A and B show 
IgG4  surface expression  before 
and after sorting respectively.  The 
solid  line shows B ceils  stained  with 
mouse  anti-human IgG4 mAb 
and the dotted line B cells stained 
with  mouse  IgG control, both 
followed  by  FITC-conjugated 
GaMlg. 
Figure  10.  Effect  of DSCG on IgG4 production induced in slgG4-B 
cells by Ib4  (50  U/m1)  and anti-CD40 mAb (5  #g/ml).  Cells  (106 
cells/m1)  were cultured for 3 d with II.-4. IgG4 then anti-CD40 was added 
with or without DSCG for 10 d. IgG4  and IgE were measured in the 
supernatants by ELISA and RIA, respectively. 
sorting we could test the effect of only two concentrations 
of DSCG,  10 -s and 10 -6 M. DSCG inhibited the secretion 
of both IgG4 and IgE (Fig. 10). In three experiments  the 
mean  _+  SD,  inhibition of IgG4  synthesis was 71  +  9% 
with 10 -6 M DSCG and 49  _+  15% with 10 -8 M DSCG. 
These results  suggest  that inhibition of isotype  switching 
by DSCG is not restricted  to IgE. 
Effect of  DSCG on Spontaneous  IgE Synthesis by B Cells  from 
Patients  with the Hylx'rimmunoglobulin  E Syndrom~  The hyper- 
IgE syndrome is a complex disorder characterized by high 
levels of  IgE, recurrent infections, and chronic dermatitis (29). 
PBMCs from patients hyper-IgE syndrome synthesize large 
quantity of IgE (30) and their circulating B cells have  under- 
gone deletional  switch  recombination (31). Table 1 shows 
that addition of up to 10 -4 M DSCG to PBMC from pa- 
tients  with the hyper-IgE syndrome resulted in only very 
modest inhibition (<15%) of spontaneous IgE production. 
These results suggested that DSCG has a minimal effect on 
IgE synthesis by B cells that have  already undergone isotype 
switching. 
DSCG Has No Effect on PWM-induced Synthesis of  lmmu- 
noglobulins byPBMC.  PWM stimulation of  PBMC induces 
T  cell-dependent synthesis of IgG and IgA in B cells that 
have previously undergone switching (Cooper,  M. D., per- 
sonal communication). This is also evidenced by the obser- 
vation that T cells from patients with X-linked hyper IgM 
syndrome that fail to induce isotype switching are capable 
of helping  normal B cells to synthesize IgG and IgA in a 
PWM-driven system (32, 33). Table 2 shows that DSCG had 
no significant effect on PWM (1 #g/ml)-induced immuno- 
globulin secretion by PBMC. These results strongly suggest 
that DSCG has no effect on immunoglobulin synthesis by 
B cells that have undergone isotype  switching. 
Discussion 
In this paper we show that DSCG inhibits IgE synthesis 
in human B cells and that this inhibition resides at the level 
of deletional switch recombination. These results suggest a 
novel potential mechanism for the prevention of allergic dis- 
ease by DSCG. 
Susceptibility of normal subjects to the inhibitory effect 
of  DSCG followed a bimodal distribution.  In approximately 
two thirds of the individuals tested, 10 -6 M DSCG resulted 
in virtual  inhibition  of IgE  synthesis by IL-4-stimulated 
PBMC. Inhibition in the remaining one third of the subjects 
was weak. The reason for this bimodal distribution is at present 
unclear. It may reflect differences in the ability of cellular 
receptors to bind DSCG or in the ability of the cells  to metabo- 
lize the drug. 
DSCG inhibited  T  cell-driven IL-4-dependent IgE syn- 
thesis  by  PBMC  in  a  dose-dependent  manner  (Fig. 1). 
Significant inhibition was observed at a concentration as low 
as 10 -s M DSCG (0.5 ng/ml). This concentration is equiva- 
lent to that found to inhibit activation of eosinophils, neu- 
trophils,  and monocytes (7). More importantly, it is in the 
range of the peak serum DSCG concentrations (16 _+ 5 ng/ml) 
attained in patients treated with inhaled DSCG (7) and well 
within the range of DSCG concentration attained locally in 
the airway after inhalation therapy for asthma (34, 35), These 
observations together with the decreased antigen-specific  IgE 
in the bronchioalveolar  lavage fluid of asthmatics who re- 
spond to DSG suggest that DSCG may downregulate IgE 
synthesis in vivo. 
Inhibition of IgE synthesis was not due to  toxicity to 
Table  1.  Effect of DSCG  on Spontaneous IgE Synthesis  by 
PBMCs from  Patients with  Hyper-IgE  Syndrome 
Net  IgE  synthesis 
DSCG  Patient no.  1  Patient no. 2 
m  pg/ml 
-  10,380  3,100 
10 -7  9,392  2,971 
10 -6  8,841  2,800 
10 -5  n.a.  2,750 
10 -4  8,916  2,713 
PBMC at a concentration of 1.5  x  106 cells/ml were cultured for 10 d 
with DSCG at a concentration of 10-6 M. Supernatants were harvested 
after 10 d and IgE levels were measured by RIA. Results for each experi- 
ment represent the mean of duplicate cultures,  n.a., samples not avail- 
able for assay. 
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Expt. no.  1  Expt. no. 2 
PWM  DSCG  IgM  IgG  IgA  IgM  IgG  IgA 
M  ng/ral  ng/ml 
-  -  150  850  90  125  750  75 
+  -  3,900  7,100  2,750  3,200  5,000  1,600 
+  10-s  4,000  7,200  2,550  2,900  4,800  1,700 
+  10 -7  3,600  6,900  3,000  3,000  4,300  1,450 
+  10 - 6  4,200  6,900  2,750  3,350  4,700  1,500 
+  10 -s  3,700  6,700  2,550  2,700  5,100  1,750 
+  10 -4  3,900  6,900  2,900  3,100  4,900  1,550 
PBMC at a concentration  of 1.5  x  106 cells/ml were cultured in the presence  of PWM (1 #g/ml) and different  concentrations  of DSCG. Superna- 
tants were harvested  after 10 d and immunoglobulin  levels  were  measured  by ELISA. Results for each  experiment  represent  the mean  of  duplicate  cultures. 
either T  or B cells.  Neither the proliferation,  nor the via- 
bility of T  or B cells were affected even at the highest con- 
centrations  of DSCG  we  used  (10 -4  M).  The  lack  of 
nonspecific toxicity is supported by the finding that DSCG 
had no effect on PWM-induced immunoglobulin synthesis 
by PBMC  (Table  2). 
DSCG did not inhibit the expression of CD40 ligand by 
T cells stimulated by PMA +  ionomycin (Fig. 2). This makes 
it unlikely that the inhibitory effect of DSCG on T cell-de- 
pendent IgE synthesis by PBMC is exerted at the level of 
the T cell. DSCG clearly targeted the B cells because it in- 
hibited IgE synthesis induced by anti-CD40 and IL-4 in B 
cell populations (Fig. 3) as well as highly purified B cells that 
have  been  positively  sorted  for  the  expression  of the  B 
cell-specific antigen CD19 (Fig. 4). We cannot, however, rule 
out an effect of DSCG on T  cells,  natural killer cells,  and 
monocytes that may contribute to the inhibition by DSCG 
of IgE synthesis, e.g., via induction of inhibitory cytokines. 
DSCG had no effect on the induction of ~ germline tran- 
scription in B cells by IL-4 (Fig. 5). In contrast, DSCG strongly 
inhibited the CD40-mediated generation of S/~ ~  Se switch 
fragments in B cells treated with IL-4 (Fig.  6).  These data 
suggest that DSCG inhibits IgE synthesis in B cells by in- 
hibiting CD40-mediated deletional switch recombination. 
Given the fact that T  cell-driven isotype switching to IgE 
involves the interaction of CD40 with its ligand on T cells 
(20),  it is likely that DSCG inhibition of T cell-dependent 
IgE synthesis in PBMC also involves  inhibition of CD40- 
mediated switch recombination in B cells. 
Engagement of CD40 results in IL-6 production (36). We 
have previously shown that IL-6 is required for optimal IgE 
synthesis because anti-IL-6 antibody strongly inhibited IgE 
synthesis by PBMC stimulated with IL-4 as well as B cells 
treated with anti-CD40  +  IL-4 (37). It is unlikely that inhi- 
bition of IgE synthesis by DSCG was due to inhibition of 
endogenous IL-6 synthesis because addition of rlL-6 did not 
reverse the inhibitory effect of DSCG on IgE synthesis (data 
not shown). 
DSCG did not inhibit all CD40-mediated signals.  Nei- 
ther CD40-mediated B cell proliferation, nor CD40-mediated 
upregulation of e germline transcript expression induced by 
IL-4, nor CD40-mediated aggregation of B cells (data not 
shown) were affected by DSCG. These observations suggest 
that inhibition of IgE synthesis by DSCG is not specific for 
the CD40 receptor but targets a discrete step in the CD40 
signaling pathway that is required for deletional switch recom- 
bination. The observation that DSCG also inhibited IgE syn- 
thesis and deletional switch recombination in B cells stimu- 
lated with hydrocortisone and IL-4 (Figs.  7 and 8) supports 
the notion that DSCG does not specifically  target CD40- 
mediated induction of isotype switching. 
Common as well as isotype-specific mechanisms are thought 
to be involved in class switching to different immunoglob- 
ulin isotypes (28). The presence of common mechanisms for 
isotype switching is supported by the finding that patients 
with X-linked hyperimmunoglobulin M syndrome, who have 
been recently shown to have deficient expression of the CD40 
ligand on their T  cells,  fail to switch to all isotypes (25). 
DSCG  inhibited  isotype  switching  to  IgG4  induced  by 
CD40  +  IL-4 (Fig.  10).  This inhibition is unlikely to be 
due to  the effect of DSCG  on IL-4-induced "Y4 germline 
transcription because DSCG inhibited IgG4 synthesis when 
added together with anti-CD40 to B cells that were prein- 
cubated for 3 d with IL-4 to allow for optimal expression 
of germline mRNA. Moreover, DSCG did not interfere with 
two effects of IL-4 we measured directly: e germline tran- 
scription and CD23 expression (data not shown). These results 
suggest  that  the  inhibitory  effect  of DSCG  on  isotype 
switching is not restricted to IgE. 
DSCG did not appear to inhibit IgE synthesis in B cells 
that have already undergone IgE isotype switching. Patients 
with the hyper-IgE syndrome have in their circulation ter- 
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pendent spontaneous IgE synthesis (30) and have circulating 
B cells that have undergone in vivo switch recombination 
to IgE (31).  IgE production by B cells from these patients 
was only minimally inhibited ('~15%) by DSCG (Table 1). 
This suggests that DSCG has little effect on IgE synthesis 
by B cells that have already undergone IgE isotype switching. 
DSCG had no effect on PWM-induced IgG and IgA syn- 
thesis by PBMC (Table 2),  a system that does not involve 
isotype switching (32,  33).  This provides further evidence 
that DSCG has no effect on immunoglobulin synthesis by 
B cells that have already undergone class switching. 
Engagement of CD40 in B cells results in the activation 
of protein tyrosine kinases (PTK) and of serine/threonine ki- 
nases including protein kinase C (PKC) (38).  Substrates for 
PTKs activated in CD40 include the src type kinase lyn, phos- 
pholipase C-*/2 and phosphoinositol-3' kinase (39).  Inhibi- 
tion of PTK activity by cross-linking CD45 to CD40 or by 
genistein results in inhibition of CD40-mediated IgE syn- 
thesis and deletional switch recombination (Loh, R., unpub- 
lished observation). In contrast, inhibition of PKC activity 
by PKC inhibitors has no effect. It will be important to ex- 
amine the effect of DSCG on PTK activation induced by CD40 
engagement. The inhibitory effect of DSCG in rat mast cells 
is assodated with the phosphorylation of a 78-kD protein 
(3). Phosphorylation of this protein occurs 30-60 s after stim- 
ulation of rat peritoneal mast cells and coincides with the 
termination of the secretory process (40).  It remains to be 
seen whether a protein of similar molecular weight is phos- 
phorylated by DSCG in B cells. 
DSCG is a water soluble salt of organic acid with a pKa 
value between 2 and 3 (41). DSCG is highly ionized at physi- 
ological pH values and is consequently unable to penetrate 
cells (35,  42). It is likely that the action of DSCG involves 
its association with a membrane receptor. Specific binding 
of DSCG to rat basophil leukemia cells (RBL-2H3) (3) and 
binding of DSCG conjugated to polyacrylamide  beads to mast 
ceils (43)  have been reported. Although these studies sup- 
port the existence of a membrane receptor for the action of 
DSCG, isolation and reconstitution of this receptor have not 
been accomplished. Further work is needed to identify and 
characterize the putative DSCG receptor. 
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